In this regard, there is much evidence in favor of the hypothesis that functional alteration of any component of the APP that can result in a novel immunopeptidome, could increase reactivity of tumor-infiltrating CD8+ T cells and sensitize tumors to ICI therapy (Figure 2). The gene discussed is APP; the disease is neoplasm.